Option Care Health (OPCH) Surges 22% on Imminent $5B Acquisition Deal

• Option Care Health (OPCH) surges 22% on reports of an imminent $5 billion acquisition deal
• OPCH is the largest independent US home infusion therapy provider — a strategically valuable acquisition target
• A 22% move reflects high deal completion probability priced in; downside risk is significant if deal fails to close

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.

Option Care Health (OPCH) shares surged approximately 22% following reports of an imminent acquisition deal valued at approximately $5 billion. Option Care Health is the largest independent provider of home and alternate site infusion therapy services in the United States, operating through a network of pharmacies and serving patients requiring complex drug infusions for conditions including immune disorders, oncology supportive care, and chronic illness management. The company's asset base — including patient relationships, pharmacy licenses, clinical staff, and payer contracts — represents significant strategic value for healthcare conglomerates seeking to expand their home health and specialty pharmacy capabilities.

The home infusion therapy sector has been a target of strategic consolidation as health systems, pharmacy benefit managers, and diversified healthcare companies seek to capture the shift toward lower-cost outpatient and home-based care delivery. Option Care Health's scale and operational expertise in complex drug administration make it a uniquely positioned acquisition target. A $5 billion deal would represent a significant premium to OPCH's pre-report market capitalization, consistent with the 22% share price movement indicating the market is pricing in deal probability at high confidence. Potential acquirers could include CVS Health, McKesson, or private equity platforms with healthcare rollup strategies.

Investors currently holding OPCH positions should evaluate the risk-reward at current prices. With a 22% gap-up already pricing in substantial deal probability, the downside from deal failure is meaningful. Monitoring deal confirmation — through official statements from OPCH management or a public announcement — is the near-term priority. If confirmed, the final deal price relative to current trading levels and the acquirer's identity will determine remaining upside. Regulatory considerations including FTC review of healthcare sector consolidation are relevant, as recent regulatory scrutiny of large healthcare M&A has increased uncertainty around deal completion timelines and conditions.